Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection

Ian White, Keyur Patel, William Symonds, Anouk Dev, Philip Griffin, Nikos Tsokanas, Mark Skehel, Chiang Liu, Amany Zekry, Paul Cutler, Mahanandeeshwar Gattu, Don Rockey, Michelle Berrey, John McHutchison

Research output: Contribution to journalArticleResearchpeer-review

40 Citations (Scopus)

Abstract

BACKGROUND: Despite its widespread use to assess fibrosis, liver biopsy has several important drawbacks, including that is it semi-quantitative, invasive, and limited by sampling and observer variability. Non-invasive serum biomarkers may more accurately reflect the fibrogenetic process. To identify potential biomarkers of fibrosis, we compared serum protein expression profiles in patients with chronic hepatitis C (CHC) virus infection and fibrosis. METHODS: Twenty-one patients with no or mild fibrosis (METAVIR stage F0, F1) and 23 with advanced fibrosis (F3, F4) were retrospectively identified from a pedigreed database of 1600 CHC patients. All samples were carefully phenotyped and matched for age, gender, race, body mass index, genotype, duration of infection, alcohol use, and viral load. Expression profiling was performed in a blinded fashion using a 2D polyacrylamide gel electrophoresis/LC-MS/MS platform. Partial least squares discriminant analysis and likelihood ratio statistics were used to rank individual differences in protein expression between the 2 groups. RESULTS: Seven individual protein spots were identified as either significantly increased (alpha2-macroglobulin, haptoglobin, albumin) or decreased (complement C-4, serum retinol binding protein, apolipoprotein A-1, and two isoforms of apolipoprotein A-IV) with advanced fibrosis. Three individual proteins, haptoglobin, apolipoprotein A-1, and alpha2-macroglobulin, are included in existing non-invasive serum marker panels. CONCLUSION: Biomarkers identified through expression profiling may facilitate the development of more accurate marker algorithms to better quantitate hepatic fibrosis and monitor disease progression.
Original languageEnglish
Pages (from-to)33 - 40
Number of pages8
JournalJournal of Translational Medicine
Volume5
Issue numberArt. No: 33
DOIs
Publication statusPublished - 2007
Externally publishedYes

Cite this